Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jonathan Corren

Showing results (101-110 of 141) with videos related to

Pageof 15
Sort By:
Journal of Immunology Research|October 30, 2023
Dupilumab Efficacy in Patients with Type 2 Asthma with and without Elevated Blood NeutrophilsEugene R Bleecker, Reynold A Panettieri, Njira L Lugogo, et al.
The Journal of Allergy and Clinical Immunology|September 16, 2021
Long-term efficacy and safety of omalizumab for nasal polyposis in an open-label extension studyPhilippe Gevaert, Rebecca Saenz, Jonathan Corren, et al.
Allergy|July 11, 2023
Dupilumab sustains efficacy in patients with moderate-to-severe type 2 asthma regardless of inhaled corticosteroids doseIan D Pavord, Arnaud Bourdin, Alberto Papi, et al.
Allergy|July 28, 2022
Dupilumab reduced impact of severe exacerbations on lung function in patients with moderate-to-severe type 2 asthmaAlberto Papi, Jonathan Corren, Mario Castro, et al.
ERJ Open Research|October 20, 2023
Impact of exacerbation history on long-term efficacy of dupilumab in patients with asthmaJonathan Corren, Constance H Katelaris, Mario Castro, et al.
The Lancet. Respiratory Medicine|January 26, 2023
Long-term safety and efficacy of tezepelumab in people with severe, uncontrolled asthma (DESTINATION): a randomised, placebo-controlled extension studyAndrew Menzies-Gow, Michael E Wechsler, Christopher E Brightling, et al.
The Journal of Allergy and Clinical Immunology|September 5, 2020
A 300 IR sublingual tablet is an effective, safe treatment for house dust mite-induced allergic rhinitis: An international, double-blind, placebo-controlled, randomized phase III clinical trialPascal Demoly, Jonathan Corren, Peter Creticos, et al.
Clinical and Experimental Allergy : Journal of the British Society for Allergy and Clinical Immunology|September 26, 2023
Efficacy of dupilumab in patients with uncontrolled, moderate-to-severe asthma with fungal sensitizationJonathan Corren, Nicola A Hanania, William W Busse, et al.
ERJ Open Research|February 25, 2026
FRONTIER-3: a randomised phase 2a study to investigate tozorakimab, an anti-interleukin-33 monoclonal antibody, in early-onset asthmaJonathan Corren, Fred Reid, Rachel Moate, et al.
The Journal of Allergy and Clinical Immunology. in Practice|February 15, 2024
Lebrikizumab in Uncontrolled Asthma: Reanalysis in a Well-Defined Type 2 PopulationJonathan Corren, Stanley J Szefler, Ellen Sher, et al.
Pageof 15

Showing results (101-110 of 141) with videos related to

Sort By:
Pageof 15
Journal of Immunology Research|October 30, 2023
Dupilumab Efficacy in Patients with Type 2 Asthma with and without Elevated Blood NeutrophilsEugene R Bleecker, Reynold A Panettieri, Njira L Lugogo, et al.
The Journal of Allergy and Clinical Immunology|September 16, 2021
Long-term efficacy and safety of omalizumab for nasal polyposis in an open-label extension studyPhilippe Gevaert, Rebecca Saenz, Jonathan Corren, et al.
Allergy|July 11, 2023
Dupilumab sustains efficacy in patients with moderate-to-severe type 2 asthma regardless of inhaled corticosteroids doseIan D Pavord, Arnaud Bourdin, Alberto Papi, et al.
Allergy|July 28, 2022
Dupilumab reduced impact of severe exacerbations on lung function in patients with moderate-to-severe type 2 asthmaAlberto Papi, Jonathan Corren, Mario Castro, et al.
ERJ Open Research|October 20, 2023
Impact of exacerbation history on long-term efficacy of dupilumab in patients with asthmaJonathan Corren, Constance H Katelaris, Mario Castro, et al.
The Lancet. Respiratory Medicine|January 26, 2023
Long-term safety and efficacy of tezepelumab in people with severe, uncontrolled asthma (DESTINATION): a randomised, placebo-controlled extension studyAndrew Menzies-Gow, Michael E Wechsler, Christopher E Brightling, et al.
The Journal of Allergy and Clinical Immunology|September 5, 2020
A 300 IR sublingual tablet is an effective, safe treatment for house dust mite-induced allergic rhinitis: An international, double-blind, placebo-controlled, randomized phase III clinical trialPascal Demoly, Jonathan Corren, Peter Creticos, et al.
Clinical and Experimental Allergy : Journal of the British Society for Allergy and Clinical Immunology|September 26, 2023
Efficacy of dupilumab in patients with uncontrolled, moderate-to-severe asthma with fungal sensitizationJonathan Corren, Nicola A Hanania, William W Busse, et al.
ERJ Open Research|February 25, 2026
FRONTIER-3: a randomised phase 2a study to investigate tozorakimab, an anti-interleukin-33 monoclonal antibody, in early-onset asthmaJonathan Corren, Fred Reid, Rachel Moate, et al.
The Journal of Allergy and Clinical Immunology. in Practice|February 15, 2024
Lebrikizumab in Uncontrolled Asthma: Reanalysis in a Well-Defined Type 2 PopulationJonathan Corren, Stanley J Szefler, Ellen Sher, et al.
Pageof 15